{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:11:08Z","timestamp":1782274268677,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The introduction of immune checkpoint inhibitors (ICI) which are designed not to activate the immune system to attack tumors but to eliminate the inhibitory signals that block antitumor T-cell responses represents a breakthrough in the treatment of malignancies. However, studies in acute lymphoblastic leukemia (ALL) patients are scarce in number and in the parameters addressed. In the present study we investigated the expression of two ICI inhibitors, PD1 and TIM3 on BM T- lymphocytes and PDL1 and Gal9 on blast cells and leukemia stem cells (LSCs) in 85 newly diagnosed ALL patients using flow cytometry. The associations and correlations with different clinical and hematological parameters were investigated. The results revealed that higher expression of these markers is associated with poor prognostic parameters in some instances and good prognostic parameters in others. These findings indicate that different prognostic parameters may have different mechanisms of action. The results of Gal9 expression on LSCs are notable. Gal9 expression on LSCs was negatively correlated with the percentage of LSCs% (<jats:italic>r<\/jats:italic>=-0.414, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) indicating that both the number and the biological characteristics of LSCs should be considered. Additionally, Low Gal9 expression on LSCs was an independent prognostic parameter for both OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.016) and PFS <jats:bold>(<\/jats:bold>\n            <jats:italic>p<\/jats:italic>\u2009=\u20090.034). This finding has not been previously reported. In conclusion this work represents a comprehensive study of some ICIs in ALL. The expression of Gal9 on LCSs may be a potential candidate for targeted therapy.<\/jats:p>","DOI":"10.1186\/s12885-025-14856-9","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T14:14:46Z","timestamp":1757686486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PD1\/PDL1 and TIM3\/Gal9 expression in acute lymphoblastic leukemia: Gal-9 expression on leukemia stem cells as an independent prognostic parameter"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-1851","authenticated-orcid":false,"given":"Azza M.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah M.","family":"Almuslimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Z.","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed AM","family":"Samra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef MS","family":"Madney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"14856_CR1","doi-asserted-by":"publisher","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 20217;7:e577. https:\/\/doi.org\/10.1038\/bcj.2017.53.","DOI":"10.1038\/bcj.2017.53"},{"key":"14856_CR2","doi-asserted-by":"publisher","unstructured":"Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann MA, Escherich G, et al. Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. Leukemia. 2020;34:2607-20. https:\/\/doi.org\/10.1038\/s41375-020-0793-1. Epub 2020 Mar 13. PMID: 32203137.","DOI":"10.1038\/s41375-020-0793-1"},{"key":"14856_CR3","doi-asserted-by":"publisher","unstructured":"Sidhu J, Gogoi MP, Krishnan S, Saha V. Relapsed Acute Lymphoblastic Leukemia. Indian J Pediatr. 2024;91:158\u2009\u2013\u200967. 2023 Jun 21. PMID: 37341952; PMCID: PMC10791726. https:\/\/doi.org\/10.1007\/s12098-023-04635-Epub","DOI":"10.1007\/s12098-023-04635-Epub"},{"key":"14856_CR4","doi-asserted-by":"publisher","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205\u2009\u2013\u200914. https:\/\/doi.org\/10.1016\/j.cell.2015.03.030","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"14856_CR5","doi-asserted-by":"publisher","unstructured":"Meng L, Wu H, Wu J, Ding P, He J, Sang M, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15:3. https:\/\/doi.org\/10.1038\/s41419-023-06389-5","DOI":"10.1038\/s41419-023-06389-5"},{"key":"14856_CR6","doi-asserted-by":"publisher","unstructured":"Solinas C, De Silva P, Bron D, Willard-Gallo K. Significance of TIM3 expression in cancer: from biology to the clinic. Semin Oncol. 2019;46:372\u201379. https:\/\/doi.org\/10.1053\/j.seminoncol.2019.08.005","DOI":"10.1053\/j.seminoncol.2019.08.005"},{"key":"14856_CR7","doi-asserted-by":"publisher","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014","DOI":"10.1016\/j.immuni.2018.03.014"},{"key":"14856_CR8","doi-asserted-by":"publisher","unstructured":"Korkmaz S, Erdem S, Akay E, Ta\u015fdemir EA, Karaman H, Keklik M. Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies? Turk J Med Sci. 2019;49:265\u201371. https:\/\/doi.org\/10.3906\/sag-1706-194","DOI":"10.3906\/sag-1706-194"},{"key":"14856_CR9","doi-asserted-by":"publisher","unstructured":"Brodsk\u00e1 B, Otev\u0159elov\u00e1 P, \u0160\u00e1lek C, Fuchs O, Ga\u0161ov\u00e1 Z, Ku\u017eelov\u00e1 K. High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations. Int J Mol Sci. 2019;20:2823. https:\/\/doi.org\/10.3390\/ijms2011282","DOI":"10.3390\/ijms2011282"},{"key":"14856_CR10","doi-asserted-by":"publisher","unstructured":"He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR. TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther. 2018;11:7005\u20139. https:\/\/doi.org\/10.2147\/OTT.S170385","DOI":"10.2147\/OTT.S170385"},{"key":"14856_CR11","doi-asserted-by":"publisher","unstructured":"Barbosa K, Deshpande AJ. Therapeutic targeting of leukemia stem cells in acute myeloid leukemia. Front Oncol. 2023;13:1204895. https:\/\/doi.org\/10.3389\/fonc.2023.1204895","DOI":"10.3389\/fonc.2023.1204895"},{"key":"14856_CR12","doi-asserted-by":"publisher","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498\u2013512. https:\/\/doi.org\/10.1038\/s41568-024-00705-7","DOI":"10.1038\/s41568-024-00705-7"},{"key":"14856_CR13","doi-asserted-by":"publisher","unstructured":"Rao A, Agrawal A, Borthakur G, Battula VL, Maiti A. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies. J Immunother Cancer. 2023;12:1\u201311. https:\/\/doi.org\/10.1136\/jitc-2023-007981","DOI":"10.1136\/jitc-2023-007981"},{"key":"14856_CR14","doi-asserted-by":"publisher","unstructured":"Sayitoglu EC, Luca BA, Boss AP, Thomas BC, Freeborn RA, Uyeda MJ, et al. AML\/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML. Leukemia. 2024;38:1246\u201355. https:\/\/doi.org\/10.1038\/s41375-024-02255-1","DOI":"10.1038\/s41375-024-02255-1"},{"key":"14856_CR15","doi-asserted-by":"publisher","unstructured":"Goetz C, Hammerbeck C. Surface and intracellular staining protocols for flow cytometry. Flow cytometry basics for the Non-Expert. Techniques in life science and biomedicine for the Non-Expert. Cham: Springer; 2018. https:\/\/doi.org\/10.1007\/978-3-319-98071-3_9","DOI":"10.1007\/978-3-319-98071-3_9"},{"key":"14856_CR16","doi-asserted-by":"crossref","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med.2006;354:166\u201378.","DOI":"10.1056\/NEJMra052603"},{"key":"14856_CR17","doi-asserted-by":"publisher","unstructured":"Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (London, England). 2007;370:240\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(07)61126-X.","DOI":"10.1016\/S0140-6736(07)61126-X"},{"key":"14856_CR18","doi-asserted-by":"publisher","unstructured":"G\u00f6kbuget N, Hoelzer D, Arnold R, B\u00f6hme A, Bartram CR, Freund M, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307-25, ix. https:\/\/doi.org\/10.1016\/s0889-8588(05)70188-x. PMID: 11147225.","DOI":"10.1016\/s0889-8588(05)70188-x"},{"key":"14856_CR19","doi-asserted-by":"publisher","unstructured":"Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber cancer Institute ALL consortium protocol95 \u2013 01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896\u2013904. https:\/\/doi.org\/10.1182\/blood-2006-06-027714","DOI":"10.1182\/blood-2006-06-027714"},{"key":"14856_CR20","doi-asserted-by":"publisher","unstructured":"Ruan Y, Wang J, Zhang Q, Wang H, Li C, Xu X, et al. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis. Eur J Med Res. 2023;28:383. https:\/\/doi.org\/10.1186\/s40001-023-01352-8","DOI":"10.1186\/s40001-023-01352-8"},{"key":"14856_CR21","doi-asserted-by":"publisher","unstructured":"Kang SH, Hwang HJ, Yoo JW, Kim H, Choi ES, Hwang SH, et al. Expression of immune checkpoint receptors on T-Cells and their ligands on leukemia blasts in childhood acute leukemia. Anticancer Res. 2019;39:5531\u201339. https:\/\/doi.org\/10.21873\/anticanres.1374","DOI":"10.21873\/anticanres.1374"},{"key":"14856_CR22","doi-asserted-by":"publisher","unstructured":"Webster JA, Luskin MR, Rimando J, Blackford A, Zeidan AM, Sharon E, et al. Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed\/Refractory (R\/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I StudyBlood. 2023;142(Supplement 1):966. https:\/\/doi.org\/10.1182\/blood-2023-191109","DOI":"10.1182\/blood-2023-191109"},{"key":"14856_CR23","doi-asserted-by":"publisher","unstructured":"Hohtari H, Br\u00fcck O, Blom S, Turkki R, Sinisalo M, Kovanen PE, et al. Immune cell constitution in bone marrowmicroenvironment predicts outcome in adult ALL. Leukemia. 2019;33:1570\u201382. https:\/\/doi.org\/10.1038\/s41375-018-0360-1","DOI":"10.1038\/s41375-018-0360-1"},{"key":"14856_CR24","doi-asserted-by":"publisher","unstructured":"Akbar A, Asgarian-Omran H, Valadan R, Dindarloo MM, Najafi A, Kahrizi A,et al. Expression of Galectin-9-related immune checkpoint receptors in B-cell acute lymphoblastic leukemia. Iranianjournal of basic medical sciences.2023;26:1468\u201374. https:\/\/doi.org\/10.22038\/IJBMS.2023.73159.15901","DOI":"10.22038\/IJBMS.2023.73159.15901"},{"key":"14856_CR25","doi-asserted-by":"publisher","unstructured":"Hamdan SO, Sughayer M, Khader M, Tbakhi A, Khudirat S, Hejazi A, et al. Programmed Death Ligand-1 is Frequently Expressed inPrimary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia. Clinical laboratory 2022;68:10.7754\/Clin.Lab.2021.210701. https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210701","DOI":"10.7754\/Clin.Lab.2021.210701"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14856-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T14:14:48Z","timestamp":1757686488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14856-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14856"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14856-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in concordance with the Helsinki Declaration and the approval of the ethics committee of NCI, Cairo University, Cairo, Egypt, approval No: No. 201920069.3; a signed informed consent was obtained from all adult patients and from the parents\/guardians of minor patients to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1421"}}